Sanofi (SNYNF) Stock Price & Analysis
Sanofi (SNYNF) — price $96.45 (0.00%), as of the Nov 19, 2026 trading session; market cap $116B.
Educational signal · not a buy or sell recommendation · How to read this
Sanofi · SNYNF · Healthcare · Drug Manufacturers - General
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Price as of Nov 19, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Thousands of the 20,000+ US stocks here carry a MoonshotScore.
Scored companies in the same industry:
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $96.45 | |
| Change on the day | 0.00% | |
| 52-week range | $76.76–$100.00 | |
| Market capitalisation | $116B | |
| Price / earnings (trailing) | 24.80 | |
| Shares traded on the day | 200 | |
| Beta (volatility vs the S&P 500) | 0.26 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Sanofi (SNYNF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Sanofi (SNYNF), and what does it report?
Short answer · as of
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. Healthcare / Drug Manufacturers General SEC filing business address: 46 Avenue DE LA Grande Armee, Paris, I0, 75017. It employs 76,493 people and is led by Belén Garijo López. In Q3 FY2026 it reported revenue of €15.23B and net income of €3.02B. The market values it at $116B.
What do the latest results show for Sanofi (SNYNF)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of €15.23B. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | €15.23B | €3.02B | €2.52 (diluted) |
| Q2 FY2026 | €12.30B | €343M | €0.29 (diluted) |
| Q1 FY2026 | €11.24B | €1.61B | €1.34 (diluted) |
| Q4 FY2025 | €23.73B | €2.00B | €1.63 (diluted) |
What are the financial strengths and risks for Sanofi (SNYNF)?
Short answer · as of
The distress and quality screens read Altman Z 1.85 · Piotroski F 8. Trailing ratios: ROE 5.7% · ROA 5.5% · current ratio 1.12.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 9
- Identified insiders
- 1
- Purchases
- 9
- Sales
- 0
- Other transactions
- 0
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SNYNF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SNYNF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Sanofi (SNYNF)?
SNYNF Healthcare Stock FAQ
Research dated 2026-09-12; the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
How do Sanofi vaccines change its revenue profile?
Vaccines add demand tied to immunization and disease prevention alongside prescription use. Pediatric combinations, respiratory protection and travel-related vaccines allow portfolio mix to shift even when therapeutic demand is stable.
What role do Sanofi research partnerships play in its pipeline?
The partnerships extend Sanofi's reach into small molecules, antibodies, protein degradation, genome editing and artificial-intelligence-assisted discovery. They widen the opportunity set while tying some development and commercialization outcomes to counterparties.
What is the SNYNF stock price today?
The last price recorded for Sanofi (SNYNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 20 figures on this page — 1 from SEC filings and earnings calls, 17 from Financial Modeling Prep (FMP) and 2 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com